Maravai Lifesciences Holdings (MRVI) Cash from Financing Activities (2020 - 2026)

Maravai Lifesciences Holdings' Cash from Financing Activities history runs 7 years deep, the most recent figure standing at -$55.2 million for Q1 2026.

• In Q1 2026, Cash from Financing Activities fell 1027.06% year-over-year to -$55.2 million; the TTM figure through Mar 2026 stood at -$66.8 million (up 72.16% YoY), while the FY2025 annual figure was -$16.5 million, up 93.0% from the prior year.
• Cash from Financing Activities was -$55.2 million for Q1 2026 at Maravai Lifesciences Holdings, down from -$1.8 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $809000.0 in Q3 2024 to a low of -$236.2 million in Q4 2024.
• Historically, Cash from Financing Activities has averaged -$32.7 million across 5 years, with a median of -$8.2 million in 2025.
• The sharpest annual moves came in 2023 and 2024: Cash from Financing Activities jumped 102.09% in 2023, then plunged 50352.98% in 2024.
• A 5-year view of Cash from Financing Activities shows it stood at -$66.1 million in 2022, then soared by 100.71% to $470000.0 in 2023, then slumped by 50352.98% to -$236.2 million in 2024, then jumped by 99.23% to -$1.8 million in 2025, then sank by 2941.08% to -$55.2 million in 2026.
• The last three Cash from Financing Activities figures came in at -$55.2 million (Q1 2026), -$1.8 million (Q4 2025), and -$8.2 million (Q3 2025), per Business Quant data.